This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2005 by Medical University of Vienna.
Recruitment status was:  Active, not recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: July 15, 2005
Last updated: October 17, 2005
Last verified: July 2005
Hepatocellular carcinoma (HCC) is a consequence of liver cirrhosis. In early tumour stages, tumour resection or liver transplantation are therapeutic options; later tumour stages may be treated with locally ablative treatments such as percutaneous ethanol instillation (PEI), transarterial chemoembolization (TACE) or radio-frequency thermoablation. This randomized study investigates the effect of PEI on survival of patients with HCC. All patients will receive hormonal treatment (long-acting somatostatin intramuscularly [i.m.]) and will be randomized for treatment with PEI or no additional treatment.

Condition Intervention Phase
Carcinoma, Hepatocellular Procedure: percutaneous ethanol instillation (PEI) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study With Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • survival time
  • time to tumour progression

Secondary Outcome Measures:
  • quality of life
  • causes of death

Estimated Enrollment: 120
Study Start Date: October 2000
Estimated Study Completion Date: July 2005
Detailed Description:

This is a randomized two-arm parallel group study.

  • Study group: PEI + long-acting somatostatin
  • Control group: long-acting somatostatin alone

Aims of the study:

  • Does treatment with PEI+ long-acting somatostatin prolong survival as compared to treatment with long-acting somatostatin alone?
  • Can time to tumour progression be extended in patients treated with PEI + long-acting somatostatin as compared to treatment with long-acting somatostatin alone?

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-proven hepatocellular carcinoma
  • Treatable with percutaneous ethanol instillation
  • Inoperable tumour
  • Age 18-85 years

Exclusion Criteria:

  • Liver cirrhosis Child C
  • Tumour diameter > 8 cm
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00121914

Universitaetsklinik fuer Innere Medizin IV / Gastroenterologie und Hepatologie
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Christian Mueller, MD Universitaetsklinik fuer Innere Medizin IV
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00121914     History of Changes
Other Study ID Numbers: HCC-327-2000
Study First Received: July 15, 2005
Last Updated: October 17, 2005

Keywords provided by Medical University of Vienna:
Carcinoma, Hepatocellular,
percutaneous ethanol instillation
long-acting somatostatin

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants processed this record on June 21, 2017